BRD4 and gastric cancer: Notably, the BRD4 inhibitor in the screen (JQ1) achieved the best synthetic lethal effect of ABE in two GC cell lines (synergy score, 24.67 in NUGC4 and 23.17 in NCI-N87), suggesting BRD4 as a candidate combination therapeutic target for ABE (Supplementary Fig. S1A).